TB-500 half-life: what the actual data shows

Last updated 2026-07-24

what is tb-500's half-life, actually

Short answer: nobody has published a solid human number. If you've seen a chart claiming TB-500 has a half-life of 4 to 6 days or "about 2 hours" or anything oddly precise, treat it with suspicion. That figure isn't sourced to a peer-reviewed human pharmacokinetic study, because one doesn't exist in the public record. What does exist is a growing body of analytical chemistry work built around doping control, plus animal metabolism studies. A 2024 paper in the Journal of Chromatography B developed a method to simultaneously quantify TB-500 and its metabolites in rats and in-vitro systems, and screened the breakdown products for wound-healing activity ^[1]. That's a real measurement of how the compound gets metabolized, in rats, not in people. It tells you TB-500 doesn't just sit around unchanged; it gets chewed up into fragments, some of which may still be biologically active. Separately, equine and human doping labs have spent over a decade building assays to detect TB-500 in urine and plasma, precisely because it clears fast and gets metabolized into pieces that are harder to catch than the parent peptide ^{[2] [3]}. That effort exists because the compound doesn't hang around long enough to be caught with simple methods. If you want the deeper backstory on how TB-500 relates to natural thymosin beta-4, that's covered on thymosin beta 4 vs tb 500.

why hasn't anyone measured tb-500's half-life in humans

Because there's no FDA-approved drug called TB-500, and no compound by that name appears in the Drugs@FDA database ^[4]. Without an approved product, nobody runs the formal Phase 1 pharmacokinetic trial that would give you a clean half-life number with confidence intervals. What gets published instead is orthopaedic and sports medicine literature describing the broader peptide therapy landscape. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics generally, including the gaps in safety and efficacy data for unapproved products ^[5]. A companion piece in The American Journal of Sports Medicine, aimed at practicing sports medicine physicians, walks through injectable peptide therapy as a category, again without offering a validated TB-500 half-life ^[6]. A third 2026 paper in Sports Medicine (Auckland) specifically reviews safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, and it treats TB-500 as squarely in the unapproved category ^[7]. So three separate 2026 clinical reviews, written for orthopaedic surgeons and sports physicians, don't hand you a half-life figure. That absence is itself informative. If the number existed in reliable form, these are exactly the papers that would cite it.

how is tb-500 different from thymosin beta-4, and does that change the half-life question

TB-500 is marketed as a synthetic version of an active region of thymosin beta-4 (Tβ4), not the full native protein. A 2012 study in Drug Testing and Analysis specifically synthesized and characterized the N-terminal acetylated 17-23 fragment of Tβ4 identified in TB-500 products, flagging it as a substance with doping potential ^[8]. That's a meaningfully different molecule from full-length Tβ4, which is 43 amino acids long. This distinction matters for half-life because smaller peptide fragments generally clear faster than larger proteins, though nobody has published a head-to-head human comparison of TB-500's fragment against full Tβ4's clearance rate. Frontiers in Aging published a 2026 review on therapeutic peptides in gerontology that discusses mechanisms and applications of peptides including Tβ4-class molecules for healthy aging, again without giving TB-500 specifically a clearance number ^[9]. If a product label or forum post uses "TB-500" and "thymosin beta-4" interchangeably, that's a red flag for sloppy sourcing. They're related but not the same compound, and conflating them muddies any pharmacokinetic claim, including half-life.

what do doping labs actually know about how fast tb-500 clears

This is where the real data lives, even though it's not framed as a clinical half-life study. Doping control chemists have been racing to detect TB-500 in urine and plasma for over a decade, and their work indirectly tells you a lot about clearance speed. A 2012 paper in the Journal of Chromatography A developed a liquid chromatography-mass spectrometry method to detect TB-500 in equine urine and plasma specifically because it's a synthetic version of an active region of Tβ4 used (and banned) in racehorses ^[2]. A 2013 paper in Analytical and Bioanalytical Chemistry expanded this to a panel of seven bioactive peptides in horse plasma, TB-500 included ^[3]. These methods exist because the compound and its metabolites move through blood and urine fast enough that timing the sample matters. A 2016 paper in the Journal of Proteomics compared multiple in-vitro model systems, proteolytic enzymes, human blood serum, liver and kidney microsomes, and liver S9 fraction, for metabolizing synthetic doping peptides including this class of compound ^[10]. Follow-up analytical work in the Journal of Separation Science (2016) built a direct urine injection method for screening peptides under 2 kDa, TB-500's fragment size falls in that range ^[11]. A 2015 paper in the Journal of Peptide Science reviewed in-vitro models for metabolic studies of small peptide hormones in sport drug testing generally ^[12]. Taken together, this literature says: TB-500 and its fragments are metabolized quickly enough by blood and tissue enzymes that anti-doping chemists had to build specialized fast-turnaround assays. That's consistent with a short half-life, likely hours rather than days, but it's an inference from analytical chemistry, not a cited clinical number.

does tb-500 stick to plastic or lab surfaces, and why does that matter for measuring it

Yes, and this is a real complication for anyone trying to pin down blood levels over time. A 2017 study in Analytical Biochemistry specifically measured adsorption effects of doping-relevant peptides, including TB-500, onto lab surfaces and found meaningful losses depending on materials used ^[13]. If a peptide sticks to the sample tube, the syringe, or the collection vial, any concentration-over-time curve built from that sample is going to underestimate what's actually circulating. That's a technical headache for researchers and it's part of why building a clean pharmacokinetic profile for TB-500 is harder than it sounds. A separate 2016 paper in Drug Testing and Analysis worked on solid-phase extraction methods for small bioactive peptides from human urine using cartridges and microelution plates, again wrestling with recovery and adsorption issues ^[14]. This is a technical detail, but it explains part of why the field hasn't converged on a clean human half-life number. The measurement problem itself is nontrivial.

how does half-life affect tb 500 dosage and injection frequency

This is the practical question behind all the chemistry. If you don't know how fast a compound clears, you can't say with confidence how often it needs to be dosed to keep blood levels in any particular range. Most dosing protocols circulating online use loading phases (more frequent dosing for several weeks) followed by maintenance dosing (less frequent), a pattern borrowed from general peptide therapy practice rather than from a TB-500-specific pharmacokinetic study. The Sports Medicine (Auckland) 2026 review notes that unapproved peptide therapies used for musculoskeletal injuries generally lack the dosing and safety data that approved drugs have ^[7], which is a broader point but directly applies to why TB-500 schedules are estimates, not evidence-based protocols. If you're trying to work out actual dosing numbers, the honest starting point is the full breakdown at tb 500 dosage, and if you want a calculator that walks through the math based on vial concentration and body weight, that's at tb-500 dosage calculator. Neither of those resources can give you a dosing frequency validated by a human half-life study, because that study doesn't exist yet. What they can do is show you the math other people are using and let you see the assumptions.

is a longer or shorter half-life better for tissue repair effects

There's no clean answer here because nobody has run the comparative study. In general pharmacology terms, a longer half-life means fewer injections to maintain a steady blood level, and a shorter half-life means levels spike and drop faster after each dose. For a peptide being explored for local tissue repair signaling rather than systemic circulating drug levels, the relevant exposure might be more about what happens at the injection site and how the fragment metabolites behave, per the 2024 Journal of Chromatography B work showing TB-500 metabolites retained wound-healing activity in-vitro ^[1]. That finding is specific to in-vitro screening in that one paper, and it hasn't been replicated in a controlled human trial. It's a reasonable hypothesis-generating result, not proof that shorter or longer half-life metabolites work better in a real injury.

is tb-500 legal, and does its half-life matter for testing

For competitive athletes, yes, and this is separate from any therapeutic question. TB-500 is prohibited under the World Anti-Doping Agency's Prohibited List, under the category covering peptides related to growth factors and tissue repair. That's exactly why the analytical chemistry literature cited above exists: anti-doping labs need methods sensitive enough to catch it and its metabolites even with a short window of detectability. A 2014 review in the Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls broadly, with TB-500-class peptides as one motivating example ^[15]. A companion 2014 review in Expert Review of Proteomics focuses specifically on detecting peptidic drugs, drug candidates, and analogs in sports doping ^[16]. If you're an athlete subject to testing, the half-life question isn't really about dosing convenience. It's about whether a short detection window creates a false sense of safety. Given how much specialized analytical work has gone into catching this specific compound, that would be a bad bet.

is tb-500 fda-approved, and how does that affect what we know about half-life

No. There's no FDA-approved drug product called TB-500 or thymosin beta-4 listed in the Drugs@FDA database ^[4]. That absence matters directly for half-life data, because FDA approval requires exactly the kind of formal pharmacokinetic study (dose escalation, blood sampling over time, elimination curve modeling) that would produce a citable human half-life. TB-500 also doesn't appear on FDA's current list of bulk drug substances nominated for use in compounding under section 503A ^[17], and it isn't on the finalized 503A bulks list under 21 CFR 216.23 ^[18] or the 503B bulks list under 21 CFR 216.24 ^[19]. Compounding pharmacies operate under 21 U.S.C. 353a ^[20], which sets conditions for compounding from bulk substances, but that legal framework is about compounding practice, not proof of a specific drug's pharmacokinetics. Practically, this means: no agency has reviewed a TB-500 half-life dataset and put its stamp on a number. Anyone quoting a precise half-life in hours or days is extrapolating, not citing a source that would hold up.

how is tb-500 actually sourced if it's not fda-approved on its own

This matters for the half-life conversation because it explains why product labeling and dosing information vary so much from one source to another. There is no standalone TB-500 product; where it's available through a provider-reviewed pathway, it's dispensed as a BPC-157/TB-500 blend rather than as an isolated TB-500 SKU. TB-500 Co works with a fulfilling pharmacy partner on that basis, through a provider-reviewed process, not as a manufacturer or compounder itself. Because it's typically supplied as a blend, any half-life or clearance discussion also has to account for BPC-157's own pharmacokinetics running in parallel, which is a separate question with its own thin evidence base. If you want the safety side of that conversation, read is tb 500 safe, and for background on where TB-500 sits in the broader research literature, start at the tb 500 hub page.

what would it take to get a real human half-life number

A formal Phase 1 pharmacokinetic study: healthy volunteers, a single administered dose, blood draws at fixed intervals (say, 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours), and mass spectrometry quantification of parent compound and metabolites at each timepoint. That's standard drug development. It hasn't been done publicly for TB-500, likely because it isn't pursuing FDA approval as a drug product. The closest proxy work is the 2024 rat and in-vitro metabolite quantification study ^[1], which used UHPLC-Q-Exactive Orbitrap MS/MS, serious analytical instrumentation, to track TB-500 breakdown in a controlled system. That's a rat model, not human, and it wasn't designed to generate a headline half-life figure so much as to identify what TB-500 turns into after it's metabolized. Until someone runs that human study, or until enough anti-doping detection-window data gets published and cross-referenced, the honest answer to "what's TB-500's half-life" stays: not established, likely short based on how fast it needs to be caught for doping control, but not pinned down with a number you should trust.

Frequently asked questions

What is the half-life of TB-500 in hours?

There's no peer-reviewed human study giving a specific number in hours. Numbers circulating online (a few hours to a couple days) are extrapolated from analytical chemistry and animal metabolism work, not from a validated human pharmacokinetic trial. Treat any precise figure you see as an estimate, not a cited fact.

Is TB-500's half-life the same as thymosin beta-4's half-life?

Not necessarily. TB-500 is a synthetic fragment (the N-terminal acetylated 17-23 region) related to native thymosin beta-4, not the identical full-length 43-amino-acid protein. Different peptide sizes generally clear at different rates, but no published study directly compares their human half-lives side by side.

Why does TB-500 need to be dosed frequently if it clears fast?

If a compound has a short half-life, blood or tissue concentrations drop quickly after each dose, so protocols use more frequent injections, especially during an initial loading phase, to try to keep exposure consistent. This logic is standard pharmacology, but no TB-500-specific human PK study has validated any particular injection frequency.

Does TB-500 show up in a drug test right away or does it take time?

Anti-doping labs have built specialized fast-turnaround liquid chromatography-mass spectrometry methods specifically because TB-500 and its metabolites move through plasma and urine quickly. That specialized effort, documented since at least 2012 in equine and human doping literature, suggests a narrow detection window rather than a long one.

Can TB-500 be detected weeks after injection?

Published detection methods focus on catching TB-500 and its metabolites in blood and urine relatively soon after administration, not weeks later. There's no published data confirming a long detectable window, and the intensity of the analytical work built around this compound suggests the opposite: a short one.

Is TB-500 FDA-approved, and does that affect how well its half-life is studied?

No, TB-500 doesn't appear in the FDA's Drugs@FDA database of approved drug products. Without formal drug approval, the type of dose-escalation pharmacokinetic study that would establish a citable half-life hasn't been conducted and published for humans.

Is TB-500 the same as a standalone product I can buy on its own?

No. Where TB-500 is available through a provider-reviewed process, it's dispensed as a BPC-157/TB-500 blend rather than sold as an isolated TB-500 product. There's no standalone TB-500 SKU in that pathway.

Does TB-500's half-life matter for athletes who get tested?

Yes. TB-500 is prohibited under the World Anti-Doping Agency's Prohibited List, and a short half-life doesn't mean a safe window from testing. Anti-doping labs have invested heavily in detecting it and its metabolites specifically because it clears fast, which makes assays harder, not because it's undetectable.

Are TB-500 metabolites still active after the parent compound breaks down?

A 2024 study in the Journal of Chromatography B found that TB-500 metabolites retained wound-healing activity in in-vitro screening after being generated from rat and lab metabolism experiments. That's a preclinical, in-vitro finding specific to that paper, not evidence of sustained activity in humans.

Why is TB-500 hard to measure accurately in blood samples?

A 2017 study in Analytical Biochemistry found that TB-500 and similar doping-relevant peptides adsorb onto lab plastics and surfaces, causing measurable losses during sample handling. This adsorption effect complicates building an accurate concentration-over-time curve, which is part of why a clean half-life hasn't been published.

How does TB-500's half-life compare to BPC-157's?

Since TB-500 is dispensed as part of a BPC-157/TB-500 blend rather than alone, the practical clearance picture involves both peptides acting in parallel. Neither compound has a well-established human half-life in peer-reviewed literature, so a direct numeric comparison isn't currently possible from published data.

Do orthopaedic or sports medicine doctors know TB-500's exact clearance rate?

Recent 2026 clinical reviews in JAAOS Global Research & Reviews, The American Journal of Sports Medicine, and Sports Medicine (Auckland) all discuss TB-500 and similar peptides as part of the unapproved therapy landscape, but none of them report a validated human half-life figure. The gap is acknowledged in the literature itself.

Sources

1. Journal of Chromatography B, 2024 (PMID 38382158): Developed UHPLC-Q-Exactive Orbitrap MS/MS method to quantify TB-500 and its metabolites in rats and in-vitro systems and screened metabolites for wound-healing activity
2. Journal of Chromatography A, 2012 (PMID 23084823): Developed LC-MS doping control method to detect TB-500 in equine urine and plasma
3. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): Developed LC-MS doping control panel detecting seven bioactive peptides including TB-500 in horse plasma
4. FDA, Drugs@FDA database: No FDA-approved drug product named TB-500 or thymosin beta-4 appears in the Drugs@FDA database
5. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedics including applications, challenges, and safety/efficacy gaps for unapproved products
6. The American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer on injectable peptide therapy for orthopaedic and sports medicine physicians without a validated TB-500 half-life
7. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries, classifying TB-500 as unapproved with limited dosing data
8. Drug Testing and Analysis, 2012 (PMID 22962027): Synthesized and characterized the N-terminal acetylated 17-23 fragment of thymosin beta-4 identified in TB-500 products with doping potential
9. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides including thymosin beta-4 class molecules in healthy aging
10. Journal of Proteomics, 2016 (PMID 27569051): Compared in-vitro model systems (proteolytic enzymes, serum, liver/kidney microsomes, liver S9 fraction) for metabolizing synthetic doping peptides
11. Journal of Separation Science, 2016 (PMID 26578461): Built a direct urine injection LC and ion mobility MS screening method for peptides under 2 kDa, the size class TB-500 fragments fall into
12. Journal of Peptide Science, 2015 (PMID 25469748): Reviewed in-vitro models used for metabolic studies of small peptide hormones in sport drug testing
13. Analytical Biochemistry, 2017 (PMID 28887173): Measured adsorption effects of doping-relevant peptides including TB-500 onto lab surfaces, causing losses during sample handling
14. Drug Testing and Analysis, 2016 (PMID 26472487): Developed solid-phase extraction methods for small bioactive peptides from human urine using cartridges and microelution plates
15. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviewed analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls
16. Expert Review of Proteomics, 2014 (PMID 25382550): Reviewed methods for detecting peptidic drugs, drug candidates, and analogs in sports doping
17. FDA, bulk drug substances nominated for compounding under 503A (current list): TB-500 does not appear on FDA's current list of bulk drug substances nominated for compounding under section 503A
18. 21 CFR 216.23, the final 503A Bulks List: TB-500 is not included on the finalized 503A bulk drug substances list under 21 CFR 216.23
19. 21 CFR 216.24, the 503B Bulks List: TB-500 is not included on the 503B bulk drug substances list under 21 CFR 216.24
20. 21 U.S.C. 353a, pharmacy compounding: Sets the legal conditions under which pharmacies may compound drug products from bulk substances